PMC:7565482 / 1747-3140 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T7","span":{"begin":888,"end":893},"obj":"Body_part"},{"id":"T8","span":{"begin":1091,"end":1095},"obj":"Body_part"},{"id":"T9","span":{"begin":1250,"end":1254},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Since the start of the COVID-19 pandemic in December 2019, researchers around the world have put major efforts towards a better understanding of the immune response to its causative agent, the SARS-CoV-2. Although an impressive amount of scientific information has been generated in a very short period of time, there remain significant gaps in our understanding of SARS-CoV-2 immune control. In particular, it remains unclear what kind of adaptive immunity should be triggered by vaccination in order to achieve sterile immunity, or at least lead to an ameliorated disease course, in cases where vaccination cannot provide absolute protection from infection. We know from the available literature on other coronaviruses (mainly SARS-CoV-1 and MERS) that antibodies can neutralize the infection, although these humoral responses are short lived in many individuals, and that long-lived T cells responses are present in people with less severe disease outcomes [1,2,3,4,5]. The emerging data on the immune response to SARS-CoV-2 demonstrate the essential contribution of the virus-specific T-cell responses, possibly in addition to the action of neutralizing antibodies, in viral control [3,6,7,8,9,10,11,12,13]. Thus, improved tools to assess host T cell immunity in detail are urgently needed to better identify these responses and to define their role in the outcome of SARS-CoV-2 infection."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T10","span":{"begin":23,"end":31},"obj":"Disease"},{"id":"T11","span":{"begin":193,"end":201},"obj":"Disease"},{"id":"T12","span":{"begin":366,"end":374},"obj":"Disease"},{"id":"T13","span":{"begin":513,"end":520},"obj":"Disease"},{"id":"T14","span":{"begin":649,"end":658},"obj":"Disease"},{"id":"T15","span":{"begin":729,"end":737},"obj":"Disease"},{"id":"T16","span":{"begin":785,"end":794},"obj":"Disease"},{"id":"T17","span":{"begin":1017,"end":1025},"obj":"Disease"},{"id":"T18","span":{"begin":1372,"end":1380},"obj":"Disease"},{"id":"T19","span":{"begin":1383,"end":1392},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005047"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Since the start of the COVID-19 pandemic in December 2019, researchers around the world have put major efforts towards a better understanding of the immune response to its causative agent, the SARS-CoV-2. Although an impressive amount of scientific information has been generated in a very short period of time, there remain significant gaps in our understanding of SARS-CoV-2 immune control. In particular, it remains unclear what kind of adaptive immunity should be triggered by vaccination in order to achieve sterile immunity, or at least lead to an ameliorated disease course, in cases where vaccination cannot provide absolute protection from infection. We know from the available literature on other coronaviruses (mainly SARS-CoV-1 and MERS) that antibodies can neutralize the infection, although these humoral responses are short lived in many individuals, and that long-lived T cells responses are present in people with less severe disease outcomes [1,2,3,4,5]. The emerging data on the immune response to SARS-CoV-2 demonstrate the essential contribution of the virus-specific T-cell responses, possibly in addition to the action of neutralizing antibodies, in viral control [3,6,7,8,9,10,11,12,13]. Thus, improved tools to assess host T cell immunity in detail are urgently needed to better identify these responses and to define their role in the outcome of SARS-CoV-2 infection."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T13","span":{"begin":119,"end":120},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T14","span":{"begin":261,"end":264},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T15","span":{"begin":283,"end":284},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T16","span":{"begin":886,"end":893},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T17","span":{"begin":1074,"end":1079},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T18","span":{"begin":1089,"end":1095},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T19","span":{"begin":1248,"end":1254},"obj":"http://purl.obolibrary.org/obo/CL_0000084"}],"text":"Since the start of the COVID-19 pandemic in December 2019, researchers around the world have put major efforts towards a better understanding of the immune response to its causative agent, the SARS-CoV-2. Although an impressive amount of scientific information has been generated in a very short period of time, there remain significant gaps in our understanding of SARS-CoV-2 immune control. In particular, it remains unclear what kind of adaptive immunity should be triggered by vaccination in order to achieve sterile immunity, or at least lead to an ameliorated disease course, in cases where vaccination cannot provide absolute protection from infection. We know from the available literature on other coronaviruses (mainly SARS-CoV-1 and MERS) that antibodies can neutralize the infection, although these humoral responses are short lived in many individuals, and that long-lived T cells responses are present in people with less severe disease outcomes [1,2,3,4,5]. The emerging data on the immune response to SARS-CoV-2 demonstrate the essential contribution of the virus-specific T-cell responses, possibly in addition to the action of neutralizing antibodies, in viral control [3,6,7,8,9,10,11,12,13]. Thus, improved tools to assess host T cell immunity in detail are urgently needed to better identify these responses and to define their role in the outcome of SARS-CoV-2 infection."}

{"project":"LitCovid-PubTator","denotations":[{"id":"37","span":{"begin":193,"end":203},"obj":"Species"},{"id":"38","span":{"begin":366,"end":376},"obj":"Species"},{"id":"39","span":{"begin":707,"end":720},"obj":"Species"},{"id":"40","span":{"begin":729,"end":737},"obj":"Species"},{"id":"41","span":{"begin":919,"end":925},"obj":"Species"},{"id":"42","span":{"begin":1017,"end":1027},"obj":"Species"},{"id":"43","span":{"begin":23,"end":31},"obj":"Disease"},{"id":"44","span":{"begin":649,"end":658},"obj":"Disease"},{"id":"45","span":{"begin":744,"end":748},"obj":"Disease"},{"id":"46","span":{"begin":785,"end":794},"obj":"Disease"},{"id":"47","span":{"begin":1372,"end":1392},"obj":"Disease"}],"attributes":[{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"Tax:2697049"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"Tax:2697049"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"Tax:11118"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"Tax:694009"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"Tax:9606"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"Tax:2697049"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:C000657245"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"MESH:D007239"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:D018352"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:D007239"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Since the start of the COVID-19 pandemic in December 2019, researchers around the world have put major efforts towards a better understanding of the immune response to its causative agent, the SARS-CoV-2. Although an impressive amount of scientific information has been generated in a very short period of time, there remain significant gaps in our understanding of SARS-CoV-2 immune control. In particular, it remains unclear what kind of adaptive immunity should be triggered by vaccination in order to achieve sterile immunity, or at least lead to an ameliorated disease course, in cases where vaccination cannot provide absolute protection from infection. We know from the available literature on other coronaviruses (mainly SARS-CoV-1 and MERS) that antibodies can neutralize the infection, although these humoral responses are short lived in many individuals, and that long-lived T cells responses are present in people with less severe disease outcomes [1,2,3,4,5]. The emerging data on the immune response to SARS-CoV-2 demonstrate the essential contribution of the virus-specific T-cell responses, possibly in addition to the action of neutralizing antibodies, in viral control [3,6,7,8,9,10,11,12,13]. Thus, improved tools to assess host T cell immunity in detail are urgently needed to better identify these responses and to define their role in the outcome of SARS-CoV-2 infection."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T3","span":{"begin":149,"end":164},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T4","span":{"begin":998,"end":1013},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"Since the start of the COVID-19 pandemic in December 2019, researchers around the world have put major efforts towards a better understanding of the immune response to its causative agent, the SARS-CoV-2. Although an impressive amount of scientific information has been generated in a very short period of time, there remain significant gaps in our understanding of SARS-CoV-2 immune control. In particular, it remains unclear what kind of adaptive immunity should be triggered by vaccination in order to achieve sterile immunity, or at least lead to an ameliorated disease course, in cases where vaccination cannot provide absolute protection from infection. We know from the available literature on other coronaviruses (mainly SARS-CoV-1 and MERS) that antibodies can neutralize the infection, although these humoral responses are short lived in many individuals, and that long-lived T cells responses are present in people with less severe disease outcomes [1,2,3,4,5]. The emerging data on the immune response to SARS-CoV-2 demonstrate the essential contribution of the virus-specific T-cell responses, possibly in addition to the action of neutralizing antibodies, in viral control [3,6,7,8,9,10,11,12,13]. Thus, improved tools to assess host T cell immunity in detail are urgently needed to better identify these responses and to define their role in the outcome of SARS-CoV-2 infection."}

{"project":"LitCovid-sentences","denotations":[{"id":"T12","span":{"begin":0,"end":204},"obj":"Sentence"},{"id":"T13","span":{"begin":205,"end":392},"obj":"Sentence"},{"id":"T14","span":{"begin":393,"end":659},"obj":"Sentence"},{"id":"T15","span":{"begin":660,"end":972},"obj":"Sentence"},{"id":"T16","span":{"begin":973,"end":1211},"obj":"Sentence"},{"id":"T17","span":{"begin":1212,"end":1393},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Since the start of the COVID-19 pandemic in December 2019, researchers around the world have put major efforts towards a better understanding of the immune response to its causative agent, the SARS-CoV-2. Although an impressive amount of scientific information has been generated in a very short period of time, there remain significant gaps in our understanding of SARS-CoV-2 immune control. In particular, it remains unclear what kind of adaptive immunity should be triggered by vaccination in order to achieve sterile immunity, or at least lead to an ameliorated disease course, in cases where vaccination cannot provide absolute protection from infection. We know from the available literature on other coronaviruses (mainly SARS-CoV-1 and MERS) that antibodies can neutralize the infection, although these humoral responses are short lived in many individuals, and that long-lived T cells responses are present in people with less severe disease outcomes [1,2,3,4,5]. The emerging data on the immune response to SARS-CoV-2 demonstrate the essential contribution of the virus-specific T-cell responses, possibly in addition to the action of neutralizing antibodies, in viral control [3,6,7,8,9,10,11,12,13]. Thus, improved tools to assess host T cell immunity in detail are urgently needed to better identify these responses and to define their role in the outcome of SARS-CoV-2 infection."}